Microtubule-associated proteins and apoptosis regulator Bcl-2 (MAPs and BCL2)

Microtubule-associated proteins (MAPs) and the apoptosis regulator Bcl-2 are distinct but functionally linked cellular components that serve as primary targets for several classes of anticancer drugs, most notably the vinca alkaloids like vinorelbine. MAPs are a diverse family of proteins, including Tau and MAP2, that regulate the stability and spatial organization of microtubules, which are essential for mitotic spindle formation and intracellular transport. Bcl-2 is a pivotal anti-apoptotic protein that maintains mitochondrial membrane integrity by sequestering pro-apoptotic proteins. Drugs targeting this axis typically bind to tubulin subunits, disrupting microtubule dynamics and interfering with MAP binding, which leads to cell cycle arrest in the G2/M phase. This disruption often triggers the phosphorylation and subsequent inactivation of Bcl-2, thereby lowering the threshold for apoptosis and leading to programmed cell death in malignant cells. This dual mechanism is particularly effective in treating various hematological malignancies and solid tumors, including non-small cell lung cancer and breast cancer.

Other names

BCL2B-cell lymphoma 2MAPsMicrotubule-binding proteinsBcl-2 family proteins

Microtubule-targeting agents (MTAs) bind to tubulin subunits, disrupting the dynamic equilibrium of microtubules and interfering with the function of microtubule-associated proteins (MAPs). This disruption leads to mitotic arrest at the metaphase-anaphase transition. Concurrently, these agents often induce the phosphorylation and inactivation of the anti-apoptotic protein Bcl-2, either directly or through the release of pro-apoptotic factors like Bim from the cytoskeleton, thereby triggering the intrinsic apoptotic pathway.